DK1450785T3 - Fremgangsmåde til behandling af dermatoser ved hjælp af en avermectin-forbindelse - Google Patents

Fremgangsmåde til behandling af dermatoser ved hjælp af en avermectin-forbindelse

Info

Publication number
DK1450785T3
DK1450785T3 DK02766531T DK02766531T DK1450785T3 DK 1450785 T3 DK1450785 T3 DK 1450785T3 DK 02766531 T DK02766531 T DK 02766531T DK 02766531 T DK02766531 T DK 02766531T DK 1450785 T3 DK1450785 T3 DK 1450785T3
Authority
DK
Denmark
Prior art keywords
avermectin compound
treating dermatoses
kit
acne
dermatitis
Prior art date
Application number
DK02766531T
Other languages
English (en)
Inventor
L Dean Parks
Original Assignee
L Dean Parks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L Dean Parks filed Critical L Dean Parks
Application granted granted Critical
Publication of DK1450785T3 publication Critical patent/DK1450785T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
DK02766531T 2001-10-12 2002-10-03 Fremgangsmåde til behandling af dermatoser ved hjælp af en avermectin-forbindelse DK1450785T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/976,915 US6399651B1 (en) 2000-06-29 2001-10-12 Method of treating dermatoses using avermectin compound
PCT/US2002/032001 WO2003032976A1 (en) 2001-10-12 2002-10-03 Method of treating dermatoses using avermectin compound

Publications (1)

Publication Number Publication Date
DK1450785T3 true DK1450785T3 (da) 2007-05-14

Family

ID=25524622

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02766531T DK1450785T3 (da) 2001-10-12 2002-10-03 Fremgangsmåde til behandling af dermatoser ved hjælp af en avermectin-forbindelse

Country Status (9)

Country Link
US (2) US6399651B1 (da)
EP (1) EP1450785B1 (da)
AT (1) ATE352298T1 (da)
CY (1) CY1106528T1 (da)
DE (1) DE60217900T2 (da)
DK (1) DK1450785T3 (da)
ES (1) ES2278046T3 (da)
PT (2) PT1450785E (da)
WO (1) WO2003032976A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897559B2 (en) * 2000-06-29 2011-03-01 Parks L Dean Dermatological composition and kit containing avermectin compound for treating dermatological conditions
US6399651B1 (en) * 2000-06-29 2002-06-04 L. Dean Parks Method of treating dermatoses using avermectin compound
FR2854074B1 (fr) * 2003-04-24 2007-11-23 Galderma Res & Dev Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
RU2350333C3 (ru) * 2003-04-24 2018-08-24 Галдерма С.А. Применение ивермектина для лечения дерматологических расстройств
GB0316377D0 (en) * 2003-07-12 2003-08-13 Norbrook Lab Ltd Parasiticidal composition
US7714015B2 (en) * 2003-08-07 2010-05-11 Lil Brat Pharmaceuticals Of Marlette, Mi Method and composition for treating sunburned skin
DE102004009904A1 (de) * 2004-02-26 2005-09-22 Grünenthal GmbH Kit aus einem gegebenenfalls wirkstoffhaltigen Pflaster und einem Hautirritationen verhindernden Mittel
FR2867684B1 (fr) * 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine
DE602005020912D1 (de) * 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme
FR2894823B1 (fr) * 2005-12-20 2008-02-29 Galderma Sa Composition de type emulsion inverse comprenant de l'ivermectine, et ses utilisations en cosmetique et en dermatologie
FR2900052B1 (fr) * 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
FR2906468B1 (fr) * 2006-09-28 2012-09-21 Galderma Sa Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
US8791153B2 (en) 2006-10-12 2014-07-29 Sanofi-Topaz, Inc. Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment-resistant strains of head lice
US8901163B2 (en) 2007-01-03 2014-12-02 Galderma S.A. Method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by insect stings or noxious weeds or plants using avermectin compound
US20080226701A1 (en) * 2007-03-15 2008-09-18 John Deignan Medicated patches
US8541022B2 (en) * 2008-06-02 2013-09-24 Galderma S.A. Method of treating burns using avermectin compound
FR2937972B1 (fr) 2008-11-04 2013-03-29 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
CA2811924C (en) 2010-10-20 2015-06-16 Galderma S.A. Method of treating hemorrhoids using macrocyclic lactone compound
CA2811926A1 (en) 2010-10-20 2012-04-26 Galderma S.A. Method of treating otitis externa using macrocyclic lactone compound
US8722636B2 (en) * 2011-01-31 2014-05-13 New Market Pharmaceuticals, LLC Animal treatments
CN102599178B (zh) * 2012-02-13 2013-11-27 中国水稻研究所 异丙威和依维菌素复配农药
AU2012379005B2 (en) 2012-05-02 2017-12-21 Newmarket Pharmaceuticals Llc Pharmaceutical compositions for direct systemic introduction
US9782425B2 (en) 2013-07-08 2017-10-10 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
US9233117B2 (en) 2013-07-08 2016-01-12 Galderma S. A. Treatment of inflammatory lesions of rosacea with ivermectin
EP3074021B1 (en) * 2013-11-29 2021-05-12 Galderma SA Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434277B (sv) * 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US5439924A (en) * 1991-12-23 1995-08-08 Virbac, Inc. Systemic control of parasites
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US5654312A (en) * 1995-06-07 1997-08-05 Andrulis Pharmaceuticals Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
US5773422A (en) * 1996-01-29 1998-06-30 Komer; Gene Avermectin formulation
US6057372A (en) * 1996-06-11 2000-05-02 Soda Aromatic Co., Ltd. Antibacterial agents and cosmetics and clothing containing the same
US5952372A (en) * 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
US6262031B1 (en) * 1999-03-12 2001-07-17 Merck & Co., Inc. Method for treating pediculosis capitisinfestation
US6133310A (en) * 1999-08-26 2000-10-17 Parks; L. Dean Method of treatment of rosacea
US6399651B1 (en) * 2000-06-29 2002-06-04 L. Dean Parks Method of treating dermatoses using avermectin compound
US6319945B1 (en) * 2000-06-29 2001-11-20 L. Dean Parks Method of treatment of seborrheic dermatitis
US6399652B1 (en) * 2000-06-29 2002-06-04 L. Dean Parks Method of treating acne vulgaris using avermectin compound

Also Published As

Publication number Publication date
ATE352298T1 (de) 2007-02-15
US20020156029A1 (en) 2002-10-24
PT1439832E (pt) 2007-06-05
EP1450785A1 (en) 2004-09-01
US6399651B1 (en) 2002-06-04
ES2278046T3 (es) 2007-08-01
DE60217900T2 (de) 2007-11-08
EP1450785B1 (en) 2007-01-24
EP1450785A4 (en) 2005-01-05
US20020035076A1 (en) 2002-03-21
WO2003032976A1 (en) 2003-04-24
DE60217900D1 (de) 2007-03-15
PT1450785E (pt) 2007-04-30
CY1106528T1 (el) 2012-01-25

Similar Documents

Publication Publication Date Title
DK1450785T3 (da) Fremgangsmåde til behandling af dermatoser ved hjælp af en avermectin-forbindelse
BR0312078A (pt) controle de informações de localização geográfica de dispositivos que operam em sistemas de comunicação sem fio
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
BRPI0506977A (pt) composto de tetrahidrocarbolina como agentes anticáncer
BRPI0413234A (pt) derivados de imidazola bicìclica contra flaviviridae
NO20080068L (no) Topisk unguale formuleringer
WO2006052600A3 (en) System and method for generating a target language markup language text template
UY27237A1 (es) Inhibidores de aldosa reductasa del grupo de las piridazinonas
BRPI0519930A2 (pt) composição oral, e, método para inibir e/ou tratar uma condição inflamatória oral em um indivìduo mamìfero
WO2005092066A3 (en) Imidazole compounds
DK1802274T3 (da) Anvendelse af cannabidiol i inhibitionen af hjernetumorcellemigration
CL2007003331A1 (es) Metodo para tratar cancer mediante la administracion de un agente radiosensibilizante derivado de benzo[a]trinden-4,6-diona; composicion farmaceutica que comprende dicho agente.
ATE417902T1 (de) Beschichtungszusammensetzung
SV2004001291A (es) Alquinos como inhibidores de metaloproteinasa de matriz ref. pc20536
NO20052028L (no) Pyridinderivater som CB2 reseptor modulatorer
WO2007101247A3 (en) Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
WO2005070043A3 (en) Methods for treating non-melanoma cancers with paba
SG165371A1 (en) Combinations comprising a vegf receptor inhibitor and a penetration enhancer
DK1423384T3 (da) Pyridinderivater som Raf kinaseinhibitorer
BRPI0719264A8 (pt) Processo para a preparação de nebivolol
ATE457308T1 (de) Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
HN2005000114A (es) Procedimiento para purificar mesotriona.
DK1562449T3 (da) Sammensætning til forbedring af fysisk præstation
WO2015017328A3 (en) Organophosphates for treating afflictions of the skin
BR0016632A (pt) Métodos e composições para a fabricação de lentes oftálmicas